🔍 A new enhancer called RevIT AAV is shown to increase the efficiency of gene therapy production by 2-4 times. It can be used with existing workflows and different cell growth media. The enhancer allows for reduced amounts of DNA, saving costs in the manufacturing process. It is compatible with multiple AAV serotypes and has been tested in various conditions. 🧬🔬🧪
📢 Revolutionary Enhancer Boosts Gene Therapy Efficiency 2-4X
Introduction:
This article discusses the use of an enhancer called RevIT AAV Enhancer, which can significantly increase the efficiency of transfection in the manufacturing of adeno-associated virus (AAV)-based gene therapies. Improvements in transfection efficiency can lead to higher productivity and lower production costs, ultimately helping to make gene therapies more affordable and accessible.
Main points:
- The RevIT AAV Enhancer is a simple-to-use product that can be easily integrated into existing workflows and has been shown to increase AAV titers by 2-4 times.
- It can be used in conjunction with transfection solutions such as TransIT-VirusGEN and conventional polymeric transfection reagents to achieve higher genome titers in suspension HEK 293 cells.
- The enhancer has been tested across multiple AAV serotypes and cell growth media, and it consistently improves genome titers and percent full capsids.
- By using the RevIT AAV Enhancer, lower amounts of plasmid DNA (pDNA) can be used, leading to significant cost savings in AAV-based gene therapy manufacturing.
- The enhancer can be easily integrated into existing AAV manufacturing workflows and doesn’t require major changes to protocols.
Conclusion:
The use of the RevIT AAV Enhancer offers a practical and effective strategy to increase AAV titers and decrease costs in the manufacturing of gene therapies. By improving transfection efficiency, this enhancer can help overcome a major bottleneck in AAV production and make gene therapies more affordable and accessible to patients.
